Wall Street Zen Upgrades EIKN (NASDAQ:EIKN) to “Hold”

EIKN (NASDAQ:EIKN) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

EIKN has been the topic of a number of other reports. Bank of America began coverage on EIKN in a report on Monday, March 2nd. They issued a “buy” rating and a $34.00 target price on the stock. Cantor Fitzgerald began coverage on EIKN in a report on Monday, March 2nd. They set an “overweight” rating for the company. Mizuho began coverage on EIKN in a research report on Monday, March 2nd. They issued an “outperform” rating and a $26.00 price target for the company. Morgan Stanley initiated coverage on EIKN in a research note on Monday, March 2nd. They issued an “overweight” rating and a $32.00 price target on the stock. Finally, Zacks Research upgraded EIKN to a “hold” rating in a report on Friday, February 27th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, EIKN has an average rating of “Moderate Buy” and a consensus price target of $25.60.

EIKN Trading Down 6.8%

NASDAQ EIKN opened at $9.81 on Friday. EIKN has a 1 year low of $9.81 and a 1 year high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.